Hemothorax cost-effectiveness of therapy: Difference between revisions
Irfan Dotani (talk | contribs) No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hemothorax}} | {{Hemothorax}} | ||
{{CMG}}; {{AE}} [[User:Irfan Dotani|Irfan Dotani]] | {{CMG}}; {{AE}} [[User:Irfan Dotani|Irfan Dotani]] {{JE}} | ||
==Overview== | |||
[[ST elevation myocardial infarction fibrinolytic therapy|Lytic Therapy]] has been tried for retained traumatic hemothorax. | |||
==Cost-effective Therapy== | |||
Avoiding surgery after treatment with any lytic agent was found to be 87% (95% CI, 81%-92%). Use of [[tissue plasminogen activator]] lead to 83% operative avoidance (95% CI, 71%-94%). Other, non-tissue plasminogen activator lytic agents lead to 87% operative avoidance (95% CI, 82%-93%). Length of stay for patients undergoing lytic therapy was 14.88 days (95% CI, 12.88-16.88) on average. [[ST elevation myocardial infarction fibrinolytic therapy|Lytic Therapy]] could decrease the need for surgical intervention in patients with retained traumatic hemothorax. [[Randomized controlled trial]]s are indicated to definitively evaluate the benefit of this therapy.<ref name="pmid30664856">{{cite journal| author=Hendriksen BS, Kuroki MT, Armen SB, Reed MF, Taylor MD, Hollenbeak CS| title=Lytic Therapy for Retained Traumatic Hemothorax: A Systematic Review and Meta-analysis. | journal=Chest | year= 2019 | volume= 155 | issue= 4 | pages= 805-815 | pmid=30664856 | doi=10.1016/j.chest.2019.01.007 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30664856 }} </ref> | |||
==References== | ==References== | ||
Revision as of 18:00, 31 August 2020
|
Hemothorax Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemothorax cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Hemothorax cost-effectiveness of therapy |
|
Risk calculators and risk factors for Hemothorax cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Irfan Dotani Joanna Ekabua, M.D. [2]
Overview
Lytic Therapy has been tried for retained traumatic hemothorax.
Cost-effective Therapy
Avoiding surgery after treatment with any lytic agent was found to be 87% (95% CI, 81%-92%). Use of tissue plasminogen activator lead to 83% operative avoidance (95% CI, 71%-94%). Other, non-tissue plasminogen activator lytic agents lead to 87% operative avoidance (95% CI, 82%-93%). Length of stay for patients undergoing lytic therapy was 14.88 days (95% CI, 12.88-16.88) on average. Lytic Therapy could decrease the need for surgical intervention in patients with retained traumatic hemothorax. Randomized controlled trials are indicated to definitively evaluate the benefit of this therapy.[1]
References
- ↑ Hendriksen BS, Kuroki MT, Armen SB, Reed MF, Taylor MD, Hollenbeak CS (2019). "Lytic Therapy for Retained Traumatic Hemothorax: A Systematic Review and Meta-analysis". Chest. 155 (4): 805–815. doi:10.1016/j.chest.2019.01.007. PMID 30664856.